Selected article for: "acute hepatitis and hepatitis infection"
Author: Varley, Cara D.; Winthrop, Kevin L.
Title: Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)
  • Cord-id: e0fahny0
  • Document date: 2021_7_16
    • ID: e0fahny0
    Snippet: PURPOSE OF REVIEW: We reviewed the current data on infections associated with rituximab use published over the last 5 years. RECENT FINDINGS: New literature was available on rates of serious infections, Hepatitis B reactivation and screening, and infection with Severe Acute Respiratory Syndrome Coronavirus 2. SUMMARY: Rates of infection varied by study and population, however, higher risk of infection in patients with underlying rheumatologic diseases was seen in those who required a therapy swi
    Document: PURPOSE OF REVIEW: We reviewed the current data on infections associated with rituximab use published over the last 5 years. RECENT FINDINGS: New literature was available on rates of serious infections, Hepatitis B reactivation and screening, and infection with Severe Acute Respiratory Syndrome Coronavirus 2. SUMMARY: Rates of infection varied by study and population, however, higher risk of infection in patients with underlying rheumatologic diseases was seen in those who required a therapy switch, had a smoking history, and those undergoing retreatment who had a serious infection with their first course of therapy. With regards to HBV, the proportion of patients screened continues to be inadequate. Despite the upfront cost, HBV screening and prophylaxis were found to be cost effective. There is still limited data regarding COVID-19 severity in the setting of rituximab, however, rituximab, especially in combination with steroids, may lead to more severe disease and higher mortality.

    Search related documents:
    Co phrase search for related documents
    • active prior and longitudinal study: 1
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and longitudinal study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute ards respiratory distress syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
    • long duration and lung disease: 1
    • longitudinal study and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • longitudinal study and lupus erythematosus: 1, 2, 3, 4
    • low immunoglobulin and lung disease: 1, 2
    • low immunoglobulin and lupus erythematosus: 1
    • low respiratory tract and lung disease: 1, 2, 3
    • lung disease and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18